A recent phase II clinical trial demonstrated that enzalutamide plus trastuzumab was well tolerated in patients with AR+/HER2+ breast cancer who were pretreated with anti-HER2 therapy, and a subset of these patients had durable disease control [13]. Here, AR is linked to breast cancer.